Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Incheon St.Mary's Hospital | OTHER |
| St Vincent's Hospital | OTHER |
| Daejeon St. Mary's hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
The aims of this study is to investigate a blood-based biomarker that can replace endoscopy in patients with inflammatory bowel disease. For this purpose, blood sample of patients wiht inflammatory bowel disease (ulcerative colitis, Crohn 's disease) was collected at the same time the endoscopy is performed, stored after centrifugation, and analyzed accordingly. Selected biomarkers from the blood sample were investigated to compare those of patients with inflammatory bowel disease and those of general controls. Males and females over the age of 19 participated in the study and are excluded if they have chronic kidney disease or blood clotting disease. The outcome is a find of a blood-based biomarker that best reflects a disease activity.
Inflammatory bowel disease refers to chronic inflammation of the unknown origin that occurs in the intestine. It usually refers to ulcerative colitis and Crohn's disease, which are idiopathic inflammatory bowel diseases. While it had been known to be a common disease in the western world, in recent decades the incidence of ulcerative colitis and Crohn's disease has rapidly increased in Korea as well. Endoscopic examination is a gold standard in order to determine the activity of inflammatory bowel disease, but it is hardly performed due to the cost and time of a test. Therefore, it is necessary to find a blood-based biomarker that replaces endoscopy. The objective of the study is to identify a new inflammatory marker that replaces endoscopy by comparing blood samples of patients with inflammatory bowel disease with those of general controls.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| inflammatory bowel disease | inflammatory bowel disease such as Ulcerative colitis and Crohn's disease |
| |
| IBS or Normal Control | irritable bowel syndrome patients normal patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| inflammatory bowel disease | Other | blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP |
|
| Measure | Description | Time Frame |
|---|---|---|
| measurement of blood-based biomarkers to predict disease activity 1 | REG3 alpha (ng/mL) | within 12 weeks of the blood sampling |
| measurement of blood-based biomarkers to predict disease activity 2 | hs-CRP (mg/dL) | within 12 weeks of the blood sampling |
| measurement of blood-based biomarkers to predict disease activity 3 | serum calprotectin (ng/mL) | within 12 weeks of the blood sampling |
| Measure | Description | Time Frame |
|---|---|---|
| Age (years) | age at the time of study enrolled | at the time of study enrolled |
| Gender (M/F) | male of female | at the time of study enrolled |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
inflammatory bowel disease (ulcerative colitis, Crohn's Dz.) irritable bowel syndrome normal control
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bo-In Lee, MD. Ph.D. | Contact | 82-10-8367-1055 | gidoc4u@gmail.com | |
| Seungjun Kim, MD. | Contact | 82-10-8786-2799 | gmt475@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Bo-In Lee, MD. Ph.D. | Seoul St. Mary's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Gastroenterology; Seoul St. Mary's hospital | Recruiting | Seoul | 137-701 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29133078 | Background | Darnaud M, Dos Santos A, Gonzalez P, Augui S, Lacoste C, Desterke C, De Hertogh G, Valentino E, Braun E, Zheng J, Boisgard R, Neut C, Dubuquoy L, Chiappini F, Samuel D, Lepage P, Guerrieri F, Dore J, Brechot C, Moniaux N, Faivre J. Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis. Gastroenterology. 2018 Mar;154(4):1009-1023.e14. doi: 10.1053/j.gastro.2017.11.003. Epub 2017 Nov 11. | |
| 26278889 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D043183 | Irritable Bowel Syndrome |
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood, Biopsy tissue, Stool
| IBS or Normal Control | Other | blood based biomarker compared normal control with IBD |
|
| disease duration (months) | duration of disease | at the time of study enrolled |
| disease onset (years) | age at which the disease begins | at the time of study enrolled |
| Background |
| Greuter T, Lang S, Holler E, Hawkey CJ, Rogler G, Biedermann L; ASTIC trial group. Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoetic Stem Cell Transplantation in the ASTIC Trial. Digestion. 2015;92(2):83-9. doi: 10.1159/000437300. Epub 2015 Aug 1. |
| 23200544 | Background | Harris AC, Levine JE, Ferrara JL. Have we made progress in the treatment of GVHD? Best Pract Res Clin Haematol. 2012 Dec;25(4):473-8. doi: 10.1016/j.beha.2012.10.010. Epub 2012 Oct 25. |
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
| D003092 | Colitis |